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Background/aim: To evaluate the effects of periodontal treatment on serum lipoprotein-associated phospholipase A2 (Lp-PLA2) and
C-reactive protein (CRP) levels in hyperlipidaemic patients with periodontitis.
Materials and methods: The study included 52 hyperlipidaemics and 28 systemically healthy controls (C) with periodontitis. Of the
52 hyperlipidaemics, 29 received a suggested diet (HD), and 23 of them were prescribed statin (HS). Clinical periodontal parameters,
serum lipids, Lp-PLA2, and CRP levels were assessed at the baseline and 2 months after the completion of the nonsurgical periodontal
treatment (2MPT). Serum parameters were also evaluated 1 week following the periodontal treatment (1WPT).
Results: At the baseline, patients in the HS group had a higher percentage of bleeding on probing than those in the C and HD groups.
Hyperlipidaemics had higher serum triglyceride levels than the control group at 2MPT compared to the baseline. At 2MPT, the levels
of Lp-PLA2 in the HS group were significantly higher compared to the baseline and 1WPT. There were no statistically significant
differences in CRP levels between study periods for all groups.
Conclusion: The periodontal treatment may affect the inflammatory control of hyperlipidaemic patients with periodontitis via increased
Lp-PLA2 levels and severity of the impaired lipid metabolism. These findings may be important regarding the therapeutic strategies for
hyperlipidaemics with periodontitis.
Key words: Periodontal treatment, hyperlipidaemia, periodontitis, lipoprotein-associated phospholipase A2, C-reactive protein

1. Introduction
Systemic inflammation and lipid deposits play a pivotal
role in atherothrombotic inception and progression (1).
Lipoprotein-associated acute phase reactants such as
C-reactive protein (CRP) (2) and lipoprotein-associated
phospholipase A2 (Lp-PLA2) (3) have been shown to
increase in acute coronary events.
Taking into account the effects of acute phase
reactants, Lp-PLA2 is a major inflammatory marker.
Lp-PLA2 has an important role in the pathogenesis of
atherosclerosis via enhanced proinflammatory cytokines,
oxidation of polyunsaturated fatty acids, and low-density
lipoprotein (LDL) cholesterol. It also plays an effective role
in endothelial cell dysfunction and cardiovascular and
thromboembolic events (3,4).
The effects of Lp-PLA2 on clinical periodontal
parameters were first reported by Lösche et al. (5).
* Correspondence: ofentoglu@yahoo.com

Individuals with moderate periodontitis had higher
Lp-PLA2 levels than periodontally healthy controls.
Furthermore, the activity of serum Lp-PLA2 decreased
after periodontal therapy in systemically healthy
individuals with periodontitis (5).
Another
lipoprotein-associated
inflammatory
mediator is CRP, which may play an important role in LDL
oxidation, complement activation, endothelial dysfunction,
and atherogenesis (6,7). A relationship between enhanced
plasma CRP levels and clinical periodontal parameters has
also been reported (8).
Although there are several studies showing
the association between periodontal disease and
hyperlipidaemia (9–11), there are only 3 studies
reporting the effects of periodontal therapy on the
metabolic and inflammatory control of lipid metabolism
in hyperlipidaemic patients (10,12,13). In our previous

619

FENTOĞLU et al. / Turk J Med Sci
studies, we suggested that periodontal therapy might
contribute to the metabolic control of hyperlipidaemia
or hypercholesterolaemia by decreasing serum
proinflammatory cytokines (12–14). Furthermore, the
role of serum CRP and Lp-PLA2 levels in the association
between periodontal disease and hyperlipidaemia was first
introduced by our colleagues (15). However, there are still
no data on the effects of periodontal therapy on the serum
levels of Lp-PLA2 and CRP in hyperlipidaemic patients.
Therefore, we aimed to evaluate the effects of periodontal
therapy on the serum levels of Lp-PLA2 and CRP in
hyperlipidaemic patients with periodontitis.
2. Materials and methods
2.1. Study population
This study was conducted by the Internal Medicine and
Periodontology Departments of Süleyman Demirel
University, Isparta, Turkey. The study was performed in
accordance with the principles outlined in the Helsinki
Declaration of 1975, as revised in 2000. The study protocol
was approved by the Ethics Committee of Süleyman
Demirel University (Date: 05.12.2006, Number: 09/11).
Informed consent was obtained from all subjects. Data
collection was performed from July 2007 to July 2009.
The study population included patients with
periodontitis who composed a part of our previous study
(15). The participants with periodontitis applied to the
Internal Medicine and/or Periodontology Department
for systemic, dental, or periodontal examination. The
hyperlipidaemic groups were made up of patients receiving
a prescribed diet (HD) or a statin antilipaemic drug (HS).
The control group was made up of systemically healthy
subjects. The study population was subjected to detailed
systemic examination to establish the medical status of the
subjects.
For the HD group, plasma LDL values were <160 mg/
dL and >130 mg/dL. For the HS group, plasma LDL values
were >160 mg/dL (16). An antilipaemic therapy that
included a lipid-lowering diet and physical activity were
recommended by the same physician (BKK) for the HD
and HS groups at the beginning of the study. Atorvastatin
(10 mg) was also prescribed for the HS group by the same
physician (BKK). Demographic characteristics such as
age, sex, body mass index (BMI) (kg/m2), and the number
of natural teeth were recorded.
Patients with the following criteria were excluded:
any systemic diseases such as impaired glucose tolerance,
diabetes mellitus, metabolic syndrome or other endocrine
disease, renal dysfunction, and cardiovascular disease;
antilipaemic treatment (diet or diet and statin therapy)
more than 1 month prior the study; any drug treatment
(such as hormone replacement, systemic antibiotic, or
antiinflammatory agent) within 3 months of the study;
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any periodontal treatment within 6 months of the study;
tobacco use (current smoker or former smoker having
quit less than 6 months prior to the study); pregnancy; and
alcohol use.
2.2. Periodontal parameters and periodontal treatment
All dental examinations were conducted by a clinician
(ÖF). The clinical periodontal parameters included
plaque index (PI) (17), gingival index (GI) (18), probing
pocket depth (PPD), clinical attachment level (CAL),
and percentage of bleeding on probing (BOP%). The
measurements were performed mesio-buccal, mid-buccal,
disto-buccal, mesio-lingual, mid-lingual, and disto-lingual
with a Williams periodontal probe (Hu-Friedy, Chicago,
IL, USA). Wisdom teeth were not evaluated. The clinical
diagnosis of chronic periodontitis was based on having at
least 4 teeth with a PPD of ≥5 mm and a CAL of ≥2 mm
at the same time (19). Subjects with chronic periodontitis
who had at least 18 natural teeth were included in the
study (20,21).
Systemic and periodontal examinations, which
included serum and clinical periodontal parameters,
were performed at baseline. Hyperlipidaemic patients
underwent diet, physical activity, and/or statin therapy
according to a physician’s recommendations (BKK) at the
beginning of the study. At the first appointment, intensive
oral hygiene instruction including tooth brushing, plaque
disclosing, and interdental cleaning as well as full mouth
scaling and polishing were performed. Blood samples
were collected in the first week after the initial visit for
periodontal treatment (1WPT) for the evaluation of serum
lipids, Lp-PLA2, and CRP levels. All of the participants
then underwent deep scaling and root planing (on a
quadrant-by-quadrant basis) by the same clinician (ÖF)
with local anaesthesia. Gracey curettes were used to do
the periodontal treatment. Systemic and periodontal
parameters were reevaluated 2 months after the completion
of the nonsurgical periodontal treatment (2MPT). For each
patient, the study protocol was completed in 3 months.
The design of the study is demonstrated in the Figure.
Intraexaminer calibration was provided by an examiner
(ÖF) with 85% accuracy.
2.3. Serum samples and laboratory analyses
At baseline (BL), the first week after initial periodontal
therapy (1WPT), and 2 months after the completion
of periodontal treatment (2MPT), blood samples were
collected in vacutainer tubes. The samples were obtained
after a 12-h fasting period from an antecubital vein.
Serum triglyceride (TRG), total cholesterol (TC), LDL,
high-density lipoprotein (HDL) cholesterol, very lowdensity lipoprotein (VLDL) cholesterol, Lp-PLA2, and
CRP levels were evaluated. Biochemical evaluations were
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Figure. Schematic of the study design.

3. Results
The study included 80 individuals aged 30–57 years,
with 52 patients with hyperlipidemia aged 30–57 and
28 controls aged 31–54. Table 1 shows the demographic
characteristics of the hyperlipidaemic and control groups.
The case and control groups did not differ significantly
in terms of age or sex (P > 0.05). Five patients in the HS
group had been receiving atorvastatin for 1 month prior
to the study. For the HS group, atorvastatin (10 mg) was
prescribed at the beginning of the study by a physician.
The statin dosage of the study population was constant
throughout the study. All of the patients complied with
the physician’s suggestions (physical activity, diet, and/or
antilipaemic drug usage) during the study period.
The periodontal and serum parameters of the study
groups are shown in Table 2. In the HS group, BOP%
values were significantly higher than in the C and HD
groups at baseline (P < 0.001). There were significant
differences in the periodontal parameters (PI, GI, BOP%,
and PPD) between 2MPT and baseline in the C, HD, and
HS groups (Table 3).
There were statistically significant increases in VLDL
levels at 1WPT compared to baseline in the C group (P =
0.003). In addition, statistically significant increases were
found in TRG levels at 2MPT compared to baseline in the
HD and HS groups (P = 0.047 and P = 0.036, respectively).
There were insignificant decreases in TC and LDL levels
of the HD and HS groups at 1WPT and 2MPT compared
to baseline (P > 0.05) (Table 3). The increases in serum
Lp-PLA2 levels at 2MPT were statistically significant

performed in the Laboratory of Clinical Biochemistry,
Faculty of Medicine, Süleyman Demirel University. The
samples were centrifuged at 4000 rpm for 4 min and the
serum was separated. The serum samples were stored at
–80 °C until the laboratory analyses were done. For the
detection of serum lipid levels, routine enzymatic methods
were used. To determine the case and control groups, the
cut-off points were: TRG > 200 mg/dL, TC > 200 mg/
dL, LDL > 130 mg/dL, HDL < 35 mg/dL, and VLDL > 40
mg/dL. Serum levels of TC, LDL, HDL, VLDL, and TRG
were determined by an autoanalyser (Olympus AU 2700,
Japan). Serum high-sensitive CRP levels were measured
by an electrochemiluminescence immunoassay using a
hormone analyser (Immulite 2000, USA). The results are
expressed in mg/L. Enzyme-linked immunosorbent assay
kits (Cayman Chemical Company, USA) were used to
determine the activity of serum Lp-PLA2. The results are
expressed mmol min–1 mL–1.
2.4. Statistical analysis
SPSS (SPSS Inc., Chicago, IL, USA) was used to perform the
statistical analysis. The power of this study was above 85%
(NCSS/PASS, 2000 Dawson Edition, Kaysville, UT, USA).
The Kolmogorov–Smirnov test was used to determine
data distribution. For the groups of normally distributed
variables, one-way analysis of variance (ANOVA) and
t-tests were used. Kruskal–Wallis one-way ANOVA and
the Mann–Whitney U test with Bonferroni’s correction
were used for nonnormally distributed variables. The
differences among the 3 study periods were assessed using
the Friedman test (P < 0.05). For post hoc analyses, the
Wilcoxon signed ranks test was used (P < 0.0167).
Table 1. Subject characteristics of the study groups.
Age (mean ± SD)
Sex, female/male (%)

43.57 ± 6.53

43.94 ± 8.39

46.60 ± 7.82

N.S.

50/50

55.20/44.8

43.5/56.5

N.S.

BMI
(median and min–max)

24.90
(19.00–32.70)

28.65
(21.23–36.87)

28.77
(24.19–39.48)

0.003*
<0.001†

Hypertension (n)

0

2

2

25.40
(19.20–32.20)

28.50
(17.75–38.70)

29.57
(23.28–38.42)

0

2

2

0.016‡
0.001§

There is a statistically significant difference between * HD and C, † HS and C at baseline (BL).
There is a statistically significant difference between ‡ HD and C, § HS and C at 2MPT. N.S. = not significant.
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3.51 (2.08–4.74)

164.00 (92.00–200.00)

96.50 (31.80–124.40)

48.00 (33.00–71.00)

17.40 (8.00–43.20)

86.00 (40.00–206.00)

8.56 (2.2–20.0)

1.75 (0.01–6.82)

TC/HDL

TC (mg/dL)

LDL (mg/dL)

HDL (mg/dL)

VLDL(mg/dL)

TRG (mg/dL)

Lp-PLA2
(mmol min –1 mL–1)

hsCRP (mg/L)

2.34 (0.01–7.82)

7.01 (3.5–76.8)

100.00 (30.00–325.00)

21.90 (6.00–65.00)

45.50 (28.00–71.00)

97.50 (47.00–154.80)

170.00 (84.00–233.00)

3.90 (2.01–6.09)

1WPT

……………

1.45 (0.02–4.92)

8.20 (10.0–90.0)

99.00 (45.00–207.00)

23.20 (10.50–41.00)

45.00 (30.00–61.00)

98.60 (27.70–148.20)

176.00 (137.00–208.00)

3.87 (2.25–5.87)

2MPT

3.08 (2.06–5.60)

45.00 (0.23–100)
3.15 (1.25–4.38)

52.18 (3.44–100)

3.07 (1.16–7.13)

1.62 (0.05–7.91)

9.31 (4.8–52.5)

125.00 (51.00–365.00)

25.00 (10.20–74.00)

43.00 (31.00–62.00)

150.00 (59.00–192.80)

220.50 (129.00–273.00)

5.25 (3.15–7.45)

BL

3.17 (1.16–7.13)

CAL (mm)

……………

2.38 (1.96–3.50)

0.91 (0.33–2.21)

1.17 (0.30–2.89)

BL

50.02 (8.38–100)

BOP (%)

……………

0.23 (0.05–0.75)

0.35 (0.12–1.20)

HD (n = 29)

2.74 (1.10–4.07)

PPD (mm)

……………

……………

C (n = 28)

1.12 (0.35–2.58)

GI

Serum
parameters

2.07 (0.68–3.00)

BL

2MPT

BL

1WPT

HD (n = 29)

C (n = 28)

PI

Periodontal
parameters

treatment (2MPT) [median (minimum–maximum)].

1.26 (0.04–4.20)

8.87 (1.3–28.7)

145.50 (68.00–382.00)

33.00 (14.00–76.00)

43.00 (33.00–123.00)

143.50 (36.00–191.00)

217.50 (155.00–277.00)

5.05 (1.52–7.48)

1WPT

……………

……………

……………

……………

……………

1WPT

0.98 (0.04–3.92)

8.60 (0.00–10.07)

154.50 (54.00–287.00)

30.80 (11.00–77.00)

43.00 (28.00–65.00)

138.20 (62.00–193.00)

214.50 (143.00–269.00)

5.11 (2.20–7.25)

2MPT

3.05 (1.94–4.05)

16.21(6.25–54.00)

2.31 (1.82–3.83)

0.22 (0.08–1.20)

0.40 (0.13–2.45)

2MPT

1.58 (0.01–9.15)

8.96 (4.6–43.9)

119.00 (45.00–686.00)

23.30 (9.00–147.00)

45.00 (29.00–68.00)

146.90 (78.60–216.00)

219.00 (143.00–347.0)

4.65 (2.96–9.00)

BL

HS (n = 23)

3.34 (1.21–4.89)

91.50 (0.60–100)

2.92 (1.77–3.87)

1.00 (0.35–2.00)

1.38 (0.58–2.84)

BL

HS (n = 23)

0.66 (0.06–7.43)

6.43 (1.3–13.5)

129.00 (41.00–303.0)

30.00 (15.00–606.00)

46.00 (32.00–57.00)

136.00 (62.0–202.40)

208.00 (131.00–298)

4.33 (2.47–8.51)

1WPT

……………

……………

……………

……………

……………

1WPT

1.35 (0.03–6.83)

11.00 (0.00–30.00)

157.50 (71.00–303.0)

39.20 (14.80–112.60)

46.00 (35.00–77.00)

130.10 (64.00–202.40)

205.50 (133.0–298.)

4.69 (2.69–8.51)

2MPT

2.92 (1.93–4.95)

15.60 (5.79–32.69)

2.30 (1.84–2.67)

0.27 (0.15–1.19)

0.40 (0.16–1.58)

2MPT

Table 2. Periodontal and serum parameters at each study period: baseline (BL), 1 week after periodontal treatment (1WPT), and 2 months after the completion of periodontal
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Table 3. Statistically significant comparisons of periodontal and serum parameters of study groups according to study periods.
Periodontal
and serum parameters

C (n = 28)

HS (n = 23)

HD (n = 29)

1WPT/BL

2MPT/1WPT

2MPT/BL

1WPT/BL

2MPT/1WPT

2MPT/BL

1WPT/BL

2MPT/1WPT

2MPT/BL

PI

N.A.

N.A.

<0.001***

N.A.

N.A.

0.002**

N.A.

N.A.

<0.001***

GI

N.A.

N.A.

<0.001***

N.A.

N.A.

<0.001***

N.A.

N.A.

0.001**

PPD (mm)

N.A.

N.A.

0.015*

N.A.

N.A.

0.049*

N.A.

N.A.

<0.001***

BOP (%)

N.A.

N.A.

<0.001***

N.A.

N.A.

<0.001***

N.A.

N.A.

0.001**

TRG (mg/dL)

N.S.

N.S.

N.S.

N.S.

N.S.

0.047*

N.S.

N.S.

0.036*

VLDL (mg/dL)

0.003*

N.S.

N.S.

N.S.

N.S.

N.S.

N.S.

N.S.

N.S.

Lp-PLA2 (mmol min–1 mL–1)

N.S.

N.S.

N.S.

N.S.

N.S.

N.S.

0.420

0.009**

0.016*

CRP (mg/L)

N.S.

N.S.

N.S.

N.S.

N.S.

N.S.

N.S.

N.S.

N.S.

*P < 0.05, **P < 0.01, ***P < 0.001. N.A. = not applicable, N.S. = not significant.
1WPT/BL = comparison of 1WPT to BL, 2MPT/1WPT = comparison of 2MPT to 1WPT, and 2MPT/BL = comparison of 2MPT to BL.

compared to baseline and 1WPT in the HS group (P =
0.016 and P = 0.009, respectively) (Table 3). There were
no statistically significant differences in serum CRP levels
among the study periods for all groups (P > 0.05).
4. Discussion
To the best of the authors’ knowledge, this is the first
study evaluating the role of periodontal therapy in serum
levels of Lp-PLA2 and CRP in hyperlipidaemic patients
with periodontitis. Serum parameters were assessed again
at 1WPT and 2MPT and periodontal parameters were
reevaluated at 2MPT because serum lipids and lipoproteins
may be modified by acute phase reactants such as LpPLA2 and CRP associated with injury or inflammation
(24,25). For the first period (1WPT), we aimed to evaluate
the effects of the early phase of wound healing associated
with mechanic instrumentation on serum inflammatory
mediators.
Strict inclusion criteria were applied in this study in
order to eradicate any systemic conditions that may play
an important role in lipid metabolism and periodontal
disease. A control group without treatment was not
considered in the present study since it could give rise
to some ethical problems regarding patients with serious
metabolic disorders such as hyperlipidaemia. Furthermore,
two different hyperlipidaemic groups (suggested diet only
and diet with atorvastatin) were composed to evaluate the
efficiency of periodontal therapy on the severity of the
impaired lipid metabolism in this study.
Our previous studies indicated that inflammatory
mediators might play a key role in the pathogenesis of
both periodontal disease and hyperlipidaemia (14,15).
However, the effects of periodontal therapy on the serum

levels of lipoprotein-associated inflammatory mediators
such as CRP and Lp-PLA2 were not investigated.
In this study, recruitment of patients was done by both
a periodontist and a physician. Although the behavioural
characteristics of the participants may affect the efficiency
of the periodontal and antilipaemic treatments, the
hyperlipidaemic patients declared that they complied with
the physician’s suggestions such as oral hygiene, physical
activity, diet, and/or antilipaemic drug usage during the
study period.
The present data showed decreases in the atherogenic
lipid profile in the hyperlipidaemic groups for both study
periods after the periodontal therapy. These findings are
in line with those reported by Oz et al. (12) and Fentoğlu
et al. (13), who showed beneficial effects of periodontal
treatment on metabolic control of hypercholesterolaemic
patients. Furthermore, these results are supported by some
reports conducted in systemically healthy subjects with
periodontitis (5,22,23).
In this study, there were insignificant increases in
serum cholesterol levels in the systemically healthy
group at 1WPT and 2MPT compared to the baseline. In
fact, acute conditions lead to an increase in cholesterol
production in humans (26). According to our results, there
were also increases in TRG and VLDL levels at 1WPT
compared to the baseline in all groups. In different types
of acute events, plasma TRG levels might increase, remain
stable, or decrease (27). Khovidhunkit et al. (28) reported
that enhanced hepatic TRG results from the stimulation of
lipolysis in peripheral and visceral adipose stores.
According to our findings, there were insignificant
decreases in serum Lp-PLA2 and CRP levels in the
controls, who were systemically healthy individuals with
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periodontitis, in both study periods. These findings are
generally consistent with the previous studies conducted
in normolipidaemic subjects with periodontitis (8).
Periodontitis led to an increase in the plasma Lp-PLA2
levels in systemically healthy subjects with periodontitis
(29). Moreover, periodontal treatment significantly
reduced the serum activity of Lp-PLA2 in systemically
healthy subjects with periodontitis (5).
According to the present results, the HD and HS
groups had higher serum Lp-PLA2 and CRP levels
compared to the C group at the baseline. However, the
HS group had the lowest serum CRP levels at the baseline.
This can be explained by the effects of statin therapy on
serum Lp-PLA2 (30) and CRP levels (31). Some beneficial
effects of statins on inflammatory mediators result from
their nonlipid effects (31). Moreover, the combination
of the periodontal therapy and antilipaemic treatment
may provide beneﬁcial effects for the metabolic and
inﬂammatory control of hyperlipidaemia by decreasing
proinflammatory cytokines (32).
In the present study, the HS group had higher
BOP% values than the HD and C groups at baseline.
The LDL content of Lp-PLA2 may be increased by acute
inflammation (33). Considering the degree of impairment
of the lipid metabolism in the HS group, the severity of
periodontal inflammation and the degree of failure of
the lipid metabolism may play important roles in the
mutual relationship between periodontal disease and
hyperlipidaemia.
In the C and HD groups, there were insignificant
reductions in serum Lp-PLA2 and CRP levels at the end
of both study periods. However, in the HS group, the
significant increase in serum Lp-PLA2 is noteworthy
at 2MPT compared to baseline and 1WPT. The
effects of periodontal therapy on serum CRP levels in
hyperlipidaemics who received statin were previously
evaluated (13). In contrast to our earlier results (13),
there were insignificant decreases in serum CRP levels in
both hyperlipidaemic groups at both study periods in the
present study. An antilipaemic therapy program including
diet, statin usage, and physical activity may also provide
additional benefits.
There is no correlation between Lp-PLA2 and
CRP regarding the determination of the risk for
cardiovascular disease (34). There was also no significant
correlation between serum Lp-PLA2 and CRP levels
in hyperlipidaemic patients with periodontal disease
according to our previous results (15). CRP is transported
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freely in the plasma rather than bound to circulating
lipoproteins (7). Therefore, it can be argued that serum
Lp-PLA2 is more important than CRP, according to the
present findings. In addition, the level of serum lipids as
well as the tissue injury due to periodontal instrumentation
may modify serum levels of Lp-PLA2 in hyperlipidaemics.
Understanding the stages involved in the pathogenesis
of Lp-PLA2 such as production, binding to circulating
lipoproteins, and the amount of Lp-PLA2 remaining free
will become more important for the hyperlipidaemic study
population. Therefore, Lp-PLA2 can be a novel target for
host modulation therapy (30,31).
Not only patients who had mild or moderate
hyperlipidaemia (HD group) but also those with severe
hyperlipidaemia (HS group) were included into this study
because the aim was to evaluate the effects of periodontal
therapy on the metabolic and inflammatory components
of hyperlipidaemia as a metabolic disorder. Periodontal
treatment led to a significant increase in serum Lp-PLA2
levels in the HS group at the end of this study period
even though the HS group received statin therapy. In
this context, the emphasis should be on the role of the
intensity of the impairment of the lipid metabolism rather
than the quantitative pathological serum lipid values
in the association between inflammation (related to
periodontitis) and hyperlipidaemia.
Finally, a combination of periodontal treatment and
lipid-lowering therapy may lead to beneficial effects on
the atherogenic lipid profile. However, the increases in
serum Lp-PLA2 levels following periodontal treatment in
hyperlipidaemics with severely impaired lipid metabolism
may suggest that the application of conventional
periodontal treatment can be combined with new
therapeutic approaches including antimicrobial and/or
antiinflammatory applications to prevent cardiovascular
events in the hyperlipidaemic population. Further
longitudinal studies in larger populations with different
severities of both periodontitis and hyperlipidaemia are
needed to clarify this association.
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